DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

BSX·Boston Scientific Corporation

$.
-. (-.%)
After Hours
High
$45.51
Open
$45.47
Market Cap
66.39B
52W High
$109.50
Low
$44.22
P. Close
$44.76
P/E
18.62
52W Low
$42.25
Fwd P/E
12.07
DailyIQ Est.
$78.89
Technical Score (1D)
27
SELL
News Sentiment
50
MIXED
Needham Research Group cut Boston Scientific’s price target to $57 from $77, citing a more cautious outlook on the company’s earnings prospects while maintaining a buy rating. The same analyst reiterated the target cut a few hours later, underscoring a consensus view of valuation pressure. A recent clinical update on the Watchman device lifted short‑term sentiment, but analysts trimmed growth expectations due to slower adoption, so the market is balancing optimism with caution. The company’s July 29 earnings are expected to show a 10.7 % YoY EPS rise and 6.5 % revenue growth, a key gauge for the next trading days. Jefferies lowered its target to $67 from $100 after revising the Watchman sales forecast to 5 % growth, highlighting concerns over the left‑atrial appendage market. Meanwhile, Boston Scientific’s $1.5 billion stake in MiRus gives it an exclusive option to acquire a nickel‑free TAVR system, positioning the firm for a potential $3 billion purchase if regulatory milestones are met. Evercore ISI also trimmed its target to $65 from $78, citing earnings‑growth concerns and competitive pressure, reinforcing the narrative of valuation headwinds. The stock trades at a low P/E of 14.56, suggesting a discount relative to peers, which could attract value‑oriented traders if earnings support the outlook. Traders should watch the July 29 earnings for guidance on revenue, margin, and the Watchman deployment data, as well as any updates on the MiRus acquisition, to gauge whether the valuation cuts are justified.
Earnings Summary
Boston Scientific Corporation (BSX) is a global medical device manufacturer focused on interventional specialties, producing devices for gastrointestinal, urological, neurological, chronic pain, cardiovascular, and heart rhythm management applications, and operating from its Marlborough, Massachusetts headquarters. In the most recent six quarters, the company has consistently outperformed EPS estimates, with Q4 2024 earnings of $0.70 versus a $0.657 estimate, Q1 2025 $0.75 versus $0.673, Q2 2025 $0.75 versus $0.725, Q3 2025 $0.75 versus $0.714, Q4 2025 $0.80 versus $0.787, and Q1 2026 $0.80 versus $0.787, demonstrating a 6‑quarter streak of EPS beats; revenue has grown from $4.561 billion in Q4 2024 to $5.286 billion in Q4 2025, a 16 % increase, before easing slightly to $5.203 billion in Q1 2026, indicating a modest slowdown in top‑line momentum. Historically, Boston Scientific has maintained a pattern of steady revenue expansion and EPS growth, with the company beating analyst expectations in every quarter reported, though the recent dip in Q1 2026 revenue suggests a potential deceleration in product adoption or pricing pressure. Recent analyst commentary has been mixed: Needham Research Group cut its price target to $57 from $77, citing a cautious outlook amid broader medical‑device headwinds, while a clinical update on the Watchman device lifted short‑term sentiment; the company’s $1.5 billion stake in MiRus also positions it for a potential $3 billion acquisition if regulatory milestones are met. Investors should watch for guidance on revenue, margin outlook, and Watchman deployment data in the upcoming earnings release, as well as any updates on the MiRus acquisition, to gauge whether the valuation cuts are justified and whether the company can sustain its earnings momentum.

EPS

EstBeatMiss
$0.65$0.70$0.75$0.80$0.85Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.83 - -
Q1'26$0.79$0.80+1.6%
Q4'25$0.79$0.80+1.6%
Q3'25$0.71$0.75+5.1%
Q2'25$0.73$0.75+3.4%
Q1'25$0.67$0.75+11.5%

Revenue

EstBeatMiss
$4.5B$4.8B$5.0B$5.3B$5.5BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.4B - -
Q1'26$5.2B$5.2B+0.6%
Q4'25$5.3B$5.3B-0.9%
Q3'25 - $5.1B -
Q2'25 - $5.1B -
Q1'25 - $4.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BSX Stock Snapshot

BSX is currently trading at $44.90, giving Boston Scientific Corporation a market cap of 66.39B and a P/E ratio of 18.6. Today's range spans $44.22–$45.51, with shares opening at $45.47 and moving up $0.14 (0.3%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 50/100.

Over the past year BSX has traded between $42.25 and $109.50 - the current price is +6.3% off the 52-week low and -59.0% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $73.86 (range $55.00–$106.00), implying upside of +64.5%.

When BSX shows a SELL (27/100) alongside neutral sentiment (50/100), the right posture for most Healthcare investors is reduced exposure rather than conviction buying. Price: $44.90 (near 52-week lows). (P/E: 18.6) At 66.39B in capitalization, the structural support levels within the $42.25–$109.50 annual range are where the setup becomes reassessable - not before.

When a large-cap Healthcare name with 66.39B in capitalization prints a SELL signal (27/100) alongside neutral news sentiment (50/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $44.90 (near 52-week lows in the $42.25–$109.50 range), the structural support levels are where that sponsorship question gets answered.